Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression

N/AApproved For MarketingNCT03924492

Supernus Pharmaceuticals, Inc.

Overview

This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial availability. Requests for access must be made by a healthcare provider for a specific patient based on a determination with patient that the benefits of treatment outweigh the risks and an assessment of eligibility based on program criteria. Sites with eligible patients must apply and meet requirements for participation in the expanded access program.

Study Type

EXPANDED_ACCESS

Conditions

Postpartum Depression

Interventions

ZULRESSO (brexanolone) injectionDRUG

ZULRESSO

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject has signed an informed consent form prior to any study-specific procedures being performed 2. Subject is an ambulatory female at least 18 years of age 3. Subject agrees to adhere to the study requirements 4. Subject agrees not to be the primary caregiver of any dependents during the infusion 5. Subject must have a negative pregnancy test on Day 1 prior to the start of the ZULRESSO infusion 6. Subject has a current diagnosis of PPD, as assessed by the Investigator Exclusion Criteria: 1. Subject has end stage renal disease 2. Subject has a known allergy to progesterone or allopregnanolone

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.